Publications by authors named "E Anne Millman"
Article Synopsis
- Gefurulimab (ALXN1720) is a bispecific antibody designed for subcutaneous treatment of chronic disorders linked to the activation of the terminal complement pathway by blocking the breakdown of complement component 5 (C5).
- It consists of specialized antibody fragments derived from llamas and humans that bind tightly to C5 and human serum albumin (HSA), enabling it to inhibit complement activity effectively in lab assays.
- Structural studies indicate that gefurulimab obstructs C5's interaction with its activating convertase, suggesting it is a strong candidate for treating complement-mediated disorders.
Background: Clinically validated biomarkers for monitoring of patients with complement-mediated thrombotic microangiopathy (CM-TMA) including atypical hemolytic uremic syndrome (aHUS) are unavailable. Improved characterization of biomarkers in patients with aHUS may inform treatment and monitoring for patients with CM-TMA.
Methods: This analysis used data collected from 55/56 (98.
Patient Safety Reporting Systems are a commonly used method for capturing information about adverse events and near misses in the acute care setting. These event reports are almost exclusively submitted by the frontline care provider, and the patient perspective of the event is rarely captured. The authors present a case which illustrates the use of eliciting the patient's perspective to provide a complementary perspective to the provider's description of the event.
View Article and Find Full Text PDF